1 |
Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-429.
DOI
|
2 |
Colombel JF, Tamboli C, Hugot JP. Clinical genetics of inflammatory bowel diseases: genetic epidemiology, genotype-phenotype correlations and pharmacogenetics. In: Kirsner's Inflammatory Bowel Diseases, 6th ed. (Sartor RB, Sandborn WJ, eds.). New Delhi: Elsevier, 2005. pp. 263-279.
|
3 |
Cucchiara S, Stronati L. Ulcerative colitis: Paediatric ulcerative colitis: can we predict proctocolectomy? Nat Rev Gastroenterol Hepatol 2012;9:494-495.
DOI
|
4 |
Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012;380:1606-1619.
DOI
|
5 |
Garcia Rodriguez LA, Gonzalez-Perez A, Johansson S, Wallander MA. Risk factors for inflammatory bowel disease in the general population. Aliment Pharmacol Ther 2005;22:309-315.
DOI
|
6 |
Mashako MN, Cezard JP, Navarro J, Mougenot JF, Sonsino E, Gargouri A, et al. Crohn's disease lesions in the upper gastrointestinal tract: correlation between clinical, radiological, endoscopic, and histological features in adolescents and children. J Pediatr Gastroenterol Nutr 1989;8:442-446.
DOI
|
7 |
Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011;365:1713-1725.
DOI
|
8 |
Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-1517.
DOI
|
9 |
Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett 2006;240:261-267.
DOI
|
10 |
Lundgren K, Montes de Oca Luna R, McNeill YB, Emerick EP, Spencer B, Barfield CR, et al. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev 1997;11:714-725.
DOI
|
11 |
Campbell IG, Eccles DM, Choong DY. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 2006;240:195-197.
DOI
|
12 |
Quesnel B, Preudhomme C, Fournier J, Fenaux P, Peyrat JP. MDM2 gene amplification in human breast cancer. Eur J Cancer 1994;30A:982-984.
|
13 |
Sotamaa K, Liyanarachchi S, Mecklin JP, Jarvinen H, Aaltonen LA, Peltomaki P, et al. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res 2005;11:6840-6844.
DOI
|
14 |
Hou H, Sun D, Zhang X. The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors. Cancer Cell Int 2019;19:216.
DOI
|
15 |
Enokida Y, Shimizu K, Kakegawa S, Atsumi J, Takase Y, Miyamae Y, et al. Single-nucleotide polymorphism (c.309T>G) in the MDM2 gene and lung cancer risk. Biomed Rep 2014;2:719-724.
DOI
|